Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Substantiation for Dietary Supplement Claims Made Under the Federal Food, Drug, and Cosmetic Act, 14021-14022 [2012-5632]
Download as PDF
14021
Federal Register / Vol. 77, No. 46 / Thursday, March 8, 2012 / Notices
counterterrorism and emergency
preparedness activities, FDA’s Center
for Devices and Radiological Health
(CDRH) began developing operational
plans and interventions that would
enable CDRH to anticipate and respond
to medical device shortages that might
arise in the context of Federally
declared disasters/emergencies or
regulatory actions. In particular, CDRH
identified the need to acquire and
maintain detailed data on domestic
inventory, manufacturing capabilities,
distribution plans, and raw material
constraints for medical devices that
would be in high demand, and/or would
be vulnerable to shortages in specific
disaster/emergency situations or
following specific regulatory actions.
Such data could support prospective
risk assessment, help inform risk
mitigation strategies, and support realtime decisionmaking by HHS during
actual emergencies or emergency
preparedness exercises.
FDA developed ‘‘The Emergency
Medical Device Shortages Program
Survey’’ in 2002 to support the
acquisition of such data from medical
device manufacturers. In 2004, CDRH
changed the process for the data
collection, and the electronic database
in which the data were stored was
formally renamed the ‘‘Emergency
Shortages Data Collection System’’
(ESDCS). Recognizing that some of the
data collected may be commercially
confidential, access to the ESDCS is
restricted to members of the CDRH
Emergency Shortage Team (EST) and
senior management with a need-toknow. At this time, the need-to-know
senior management personnel are
limited to two senior managers. Further,
the data are used by this defined group
only for decisionmaking and planning
in the context of a Federally declared
disaster/emergency, an official
emergency preparedness exercise, or a
potential public health risk posed by
non-disaster-related device shortage.
The data procurement process
consists of an initial scripted telephone
call to a regulatory officer at a registered
manufacturer of one or more key
medical devices tracked in the ESDCS.
In this initial call, the EST member
describes the intent and goals of the
data collection effort and makes the
specific data request. After the initial
call, one or more additional followup
calls and/or electronic mail
correspondence may be required to
verify/validate data sent from the
manufacturer, confirm receipt, and/or
request additional detail. Although the
regulatory officer is the agent who the
EST member initially contacts,
regulatory officers may designate an
alternate representative within their
organization to correspond subsequently
with the CDRH EST member who is
collecting or verifying/validating the
data.
Because of the dynamic nature of the
medical device industry, particularly
with respect to specific product lines,
manufacturing capabilities, and raw
material/subcomponent sourcing, it is
necessary to update the data in the
ESDCS at regular intervals. The EST
makes such updates on a regular basis,
but makes efforts to limit the frequency
of outreach to a specific manufacturer to
no more than every 4 months.
The ESDCS will only include those
medical devices for which there will
likely be high demand during a specific
emergency/disaster, or for which there
are sufficiently small numbers of
manufacturers such that disruption of
manufacture or loss of one or more of
these manufacturers would create a
shortage.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
Section of the FD&C Act
903(d)(2) ..............................................................................
wreier-aviles on DSK5TPTVN1PROD with NOTICES
1
Number of
responses per
respondent
125
Total annual
responses
3
375
Average burden per
response
Total hours
0.5
188
There are no capital costs or operating and maintenance costs associated with this collection of information.
FDA based the burden estimates in
table 1 of this document on past
experience with direct contact with the
medical device manufacturers and
anticipated changes in the medical
device manufacturing patterns for the
specific devices being monitored. FDA
estimates that approximately 125
manufacturers would be contacted by
telephone and/or electronic mail 3 times
per year either to obtain primary data or
to verify/validate data. Because the
requested data represent data elements
that are monitored or tracked by
manufacturers as part of routine
inventory management activities, it is
anticipated that for most manufacturers,
the estimated time required of
manufacturers to complete the data
request will not exceed 30 minutes per
request cycle.
Dated: March 2, 2012.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2012–5633 Filed 3–7–12; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0403]
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Substantiation for Dietary Supplement
Claims Made Under the Federal Food,
Drug, and Cosmetic Act
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
SUMMARY:
VerDate Mar<15>2010
15:20 Mar 07, 2012
Jkt 226001
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
that a collection of information entitled
‘‘Substantiation for Dietary Supplement
Claims Made Under the Federal Food,
Drug, and Cosmetic Act’’ has been
approved by the Office of Management
and Budget (OMB) under the Paperwork
Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT:
Denver Presley, II, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
3793.
On August
30, 2011, the Agency submitted a
proposed collection of information
entitled ’’ Substantiation for Dietary
Supplement Claims Made Under the
Federal Food, Drug, and Cosmetic Act’’
to OMB for review and clearance under
44 U.S.C. 3507. An Agency may not
conduct or sponsor, and a person is not
required to respond to, a collection of
information unless it displays a
currently valid OMB control number.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\08MRN1.SGM
08MRN1
14022
Federal Register / Vol. 77, No. 46 / Thursday, March 8, 2012 / Notices
OMB has now approved the information
collection and has assigned OMB
control number 0910–0626. The
approval expires on February 28, 2015.
A copy of the supporting statement for
this information collection is available
on the Internet at https://
www.reginfo.gov/public/do/PRAMain.
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852.
Dated: March 2, 2012.
Leslie Kux,
Acting Assistant Commissioner for Policy.
SUPPLEMENTARY INFORMATION:
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–D–0112]
Guidance for Industry on Chemistry,
Manufacturing, and Controls
Information—Fermentation-Derived
Intermediates, Drug Substances, and
Related Drug Products for Veterinary
Medicinal Use; Availability
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of a guidance for industry
#216 entitled ‘‘Chemistry,
Manufacturing, and Controls (CMC)
Information—Fermentation-Derived
Intermediates, Drug Substances, and
Related Drug Products for Veterinary
Medicinal Use.’’
The purpose of this document is to
provide recommendations on what
documentation to submit to support the
CMC information for fermentationderived intermediates, drug substances,
and related drug products for veterinary
medicinal use.
DATES: Submit either electronic or
written comments on Agency guidances
at any time.
ADDRESSES: Submit written requests for
single copies of the guidance to the
Communications Staff (HFV–12), Center
for Veterinary Medicine, Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855. Send one selfaddressed adhesive label to assist that
office in processing your requests. See
the SUPPLEMENTARY INFORMATION section
for electronic access to the guidance
document.
Submit electronic comments on the
guidance to https://www.regulations.gov.
Submit written comments to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
wreier-aviles on DSK5TPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
15:20 Mar 07, 2012
Jkt 226001
Michael J. Popek, Center for Veterinary
Medicine (HFV–144), Food and Drug
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 240–276–8269,
email: michael.popek@fda.hhs.gov.
I. Background
[FR Doc. 2012–5632 Filed 3–7–12; 8:45 am]
AGENCY:
FOR FURTHER INFORMATION CONTACT:
This level 1 guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance will represent the
Agency’s current thinking on this topic.
It does not create or confer any rights for
or on any person and does not operate
to bind FDA or the public. An
alternative approach may be used if
such approach satisfies the
requirements of the applicable statutes
and regulations.
III. Paperwork Reduction Act of 1995
This guidance refers to previously
approved collections of information
found in FDA regulations. These
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). The collections of information in
this guidance have been approved under
OMB control number 0910–0032.
IV. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) either electronic or written
comments regarding this document. It is
only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
Fmt 4703
Sfmt 4703
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–D–0091]
Guidance for Industry: Testing for
Salmonella Species in Human Foods
and Direct-Human-Contact Animal
Foods; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or the Agency) is
announcing the availability of a
guidance entitled ‘‘Guidance for
Industry: Testing for Salmonella Species
in Human Foods and Direct-HumanContact Animal Foods.’’ The document
provides guidance to firms that
manufacture, process, pack, or hold
human foods or direct-human-contact
animal foods intended for distribution
to consumers, institutions, or food
processors. This guidance does not
apply to egg producers and other
persons who are covered by FDA’s final
rule ‘‘Prevention of Salmonella
Enteritidis in Shell Eggs During
Production, Storage, and
Transportation.’’ The guidance
addresses testing procedures for
Salmonella species (spp.) in human
foods (except shell eggs) and directhuman-contact animal foods, and the
interpretation of test results, when the
presence of Salmonella spp. in the food
may render the food injurious to human
health.
DATES: Submit either electronic or
written comments on Agency guidances
at any time.
ADDRESSES: Submit written requests for
single copies of the guidance to the
Office of Food Safety, Center for Food
Safety and Applied Nutrition, (HFS–
317), Food and Drug Administration,
5100 Paint Branch Pkwy., College Park,
MD 20740. Send two self-addressed
adhesive labels to assist that office in
processing your request. See the
SUMMARY:
II. Significance of Guidance
Frm 00024
Dated: March 5, 2012.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2012–5629 Filed 3–7–12; 8:45 am]
In the Federal Register of March 14,
2011 (76 FR 13629), FDA published the
notice of availability for a draft guidance
entitled ‘‘Chemistry, Manufacturing,
and Controls (CMC) Information—
Fermentation-Derived Intermediates,
Drug Substances, and Related Drug
Products for Veterinary Medicinal Use’’
giving interested persons until May 30,
2011, to comment on the draft guidance.
FDA received one comment on the draft
guidance. No substantive changes were
made in finalizing this guidance
document.
The guidance announced in this
notice finalizes the draft guidance dated
March 14, 2012.
PO 00000
V. Electronic Access
Persons with access to the Internet
may obtain the guidance at either
https://www.fda.gov/AnimalVeterinary/
GuidanceComplianceEnforcement/
GuidanceforIndustry/default.htm or
https://www.regulations.gov.
E:\FR\FM\08MRN1.SGM
08MRN1
Agencies
[Federal Register Volume 77, Number 46 (Thursday, March 8, 2012)]
[Notices]
[Pages 14021-14022]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-5632]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0403]
Agency Information Collection Activities; Announcement of Office
of Management and Budget Approval; Substantiation for Dietary
Supplement Claims Made Under the Federal Food, Drug, and Cosmetic Act
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
collection of information entitled ``Substantiation for Dietary
Supplement Claims Made Under the Federal Food, Drug, and Cosmetic Act''
has been approved by the Office of Management and Budget (OMB) under
the Paperwork Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT: Denver Presley, II, Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.,
PI50-400B, Rockville, MD 20850, 301-796-3793.
SUPPLEMENTARY INFORMATION: On August 30, 2011, the Agency submitted a
proposed collection of information entitled '' Substantiation for
Dietary Supplement Claims Made Under the Federal Food, Drug, and
Cosmetic Act'' to OMB for review and clearance under 44 U.S.C. 3507. An
Agency may not conduct or sponsor, and a person is not required to
respond to, a collection of information unless it displays a currently
valid OMB control number.
[[Page 14022]]
OMB has now approved the information collection and has assigned OMB
control number 0910-0626. The approval expires on February 28, 2015. A
copy of the supporting statement for this information collection is
available on the Internet at https://www.reginfo.gov/public/do/PRAMain.
Dated: March 2, 2012.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2012-5632 Filed 3-7-12; 8:45 am]
BILLING CODE 4160-01-P